InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,584.54
(
-0.88%
)
US TECH 100
19,686.40
(
-2.15%
)
Dow Jones
39,753.75
(
0.08%
)
Brent Oil
85.17
(
0.14%
)
Bitcoin
57,517.25
(
-0.41%
)
Post# of 252575
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

vinmantoo

Send PM Follow Ignore
Followers 30
Posts 4146
Boards Moderated 0
Alias Born 07/25/2007

vinmantoo

Re: DewDiligence post# 248702

Wednesday, 08/16/2023 12:13:49 PM

Wednesday, August 16, 2023 12:13:49 PM

Post# of 252575

SGEN’s Tukysa shows statsig-superior PFS as addend to Kadcyla in second-line HER2+ breast cancer phase-3 trial:..... No hazard ratio is reported—details to come at an unspecified medical conference. OS data (a secondary endpoint) are not yet mature.



Glad to see it met the primary end point of PFS. SGEN’s but it would have been nice to see the data. Oh well, that will come soon enough.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up